CNS Pharmaceuticals (CNSP) vs Ensysce Biosciences (ENSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ensysce Biosciences is the larger company by market cap ($8.9 million vs $7.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CNSP | ENSC |
|---|---|---|
| Share price | $5.35 | $0.458 |
| Market cap | $7.82M | $8.91M |
| 1-day change | -1.47% | +6.66% |
| EPS (TTM) | $-17.90 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.56 | $2.75 |
| 52-week low | $1.90 | $0.23 |
| Distance from 52-week high | -49.34% | -83.35% |
| Analyst consensus | none | none |
| Avg. price target upside | +86.92% | +1701.31% |
| Average volume | 6.52K | 14.19M |
| Shares outstanding | 1.46M | 19.46M |
| Employees | 8 | 8 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Healthcare · Biotechnology · 8 employees
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Healthcare · Biotechnology · 8 employees
CNSP vs ENSC FAQ
Which is bigger, CNS Pharmaceuticals or Ensysce Biosciences?
Ensysce Biosciences (ENSC) is larger, with a market capitalization of $8.91M compared with $7.82M for CNS Pharmaceuticals (CNSP).
Are CNS Pharmaceuticals and Ensysce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.